- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Misoprostol safe alternative to mifepristone for first-trimester medication abortion
Medical abortion is a procedure in which prescription drugs are used to terminate pregnancy without resorting to any surgical procedure. Usually it is performed through the ninth week of pregnancy and involves taking two medications — mifepristone and misoprostol. Mifepristone works by blocking the hormone progesterone without which the pregnancy cannot continue to grow in the uterus. However Misoprostol causes cramping and bleeding to empty the uterus.
Dr Elizabeth G. Raymond and associates have found in a new study that Misoprostol-only is an effective and safe option for terminating a first trimester intrauterine pregnancy when mifepristone is unavailable or inaccessible, according to there recent study results.
The study's main objective was to update the 2019 systematic data review on the effectiveness and safety of misoprostol-only for first-trimester abortion.
The team searched PubMed and found articles describing outcomes of treatment with misoprostol-only for abortion of viable intrauterine pregnancy at ≤91 days of gestation. They assessed bias risk using four defined indicators.
They estimated treatment failure proportions using meta-analytic methods and the proportion of hospitalized or transfused after treatment.
The team examined associations between treatment failure and selected characteristics of the groups.
The key results of the study are:
- They identified 49 papers with 66 groups, including 16,354 evaluable patients.
- Two thousand nine hundred sixty patients had treatment failures.
- Out of 9,228 patients assessed, 521 had that condition.
- There was an association of the Failure risk with misoprostol dose, the total allowed number of doses, the maximum dosing duration and indicators of bias risk.
- Among 11,007 patients allowed to take at least three misoprostol doses, the first consisting of misoprostol 800 mcg administered vaginally, sublingually, or buccally, the meta-analytic estimate of the failure risk was 11%.
- 0.2% of 15,679 evaluable patients were hospitalized or received transfusions.
Concluding further, they said the results continue to support the key conclusion of our 2019 analysis.
According to researchers Misoprostol-only is effective and safe for first trimester intrauterine pregnancy termination, if mifepristone is unavailable or inaccessible.
Further reading:
https://www.contraceptionjournal.org/article/S0010-7824(23)00226-3/fulltext
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751